JP2538816B2 - Vitamin A preparation for animals - Google Patents
Vitamin A preparation for animalsInfo
- Publication number
- JP2538816B2 JP2538816B2 JP3258750A JP25875091A JP2538816B2 JP 2538816 B2 JP2538816 B2 JP 2538816B2 JP 3258750 A JP3258750 A JP 3258750A JP 25875091 A JP25875091 A JP 25875091A JP 2538816 B2 JP2538816 B2 JP 2538816B2
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- preparation
- fatty acid
- chain fatty
- animals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 title claims description 34
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 title claims description 33
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 title claims description 33
- 235000019155 vitamin A Nutrition 0.000 title claims description 33
- 239000011719 vitamin A Substances 0.000 title claims description 33
- 229940045997 vitamin a Drugs 0.000 title claims description 33
- 238000002360 preparation method Methods 0.000 title claims description 18
- 241001465754 Metazoa Species 0.000 title claims description 12
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 15
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 15
- 239000004094 surface-active agent Substances 0.000 claims description 10
- 150000005846 sugar alcohols Polymers 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 16
- 239000000203 mixture Substances 0.000 description 9
- 229930003427 Vitamin E Natural products 0.000 description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 8
- 235000019165 vitamin E Nutrition 0.000 description 8
- 229940046009 vitamin E Drugs 0.000 description 8
- 239000011709 vitamin E Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- -1 polyoxyethylene glycerin Polymers 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- 239000005643 Pelargonic acid Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
【０００１】[0001]
【産業上の利用分野】本発明は、飼育用動物に投与する
ためのビタミンＡ製剤に関する。更に詳しくは、本発明
はビタミンＡ組成物に中鎖脂肪酸トリグリセリドを配合
することにより、ビタミンＡの動物の体内への吸収性を
高めた動物用ビタミンＡ製剤に関するものである。FIELD OF THE INVENTION The present invention relates to a vitamin A preparation for administration to domestic animals. More specifically, the present invention relates to a vitamin A preparation for animals in which absorption of vitamin A into the body of an animal is improved by incorporating a medium chain fatty acid triglyceride into the vitamin A composition.
【０００２】[0002]
【従来の技術】従来、飼育用動物にビタミンＡを投与す
る際には、これを水溶化製剤として、飲水に溶解させて
投与させる。ビタミンＡの水可溶化製剤は、油状のビタ
ミンＡを界面活性剤単独あるいは界面活性剤と多価アル
コールを組み合わせたものを加えて混合攪拌し、これに
水を加えて調製されていた。2. Description of the Related Art Conventionally, when vitamin A is administered to domestic animals, it is dissolved in drinking water and administered as a water-soluble preparation. The water-solubilized preparation of vitamin A was prepared by adding oily vitamin A to a surfactant alone or a combination of a surfactant and a polyhydric alcohol, mixing and stirring, and then adding water thereto.
【０００３】[0003]
【発明が解決すべき課題】この製剤は、飲水に溶解して
動物に投与されるが、動物の体内におけるビタミンＡの
吸収は必ずしも十分であるとはいえず、必然的に投与量
を多くしなければならないのが現状であった。従って、
本発明の目的は、水によく溶け、かつ動物に経口投与し
た場合に優れた吸収性を示すビタミンＡ製剤を提供する
ことにある。This preparation is dissolved in drinking water and administered to animals. However, absorption of vitamin A in the body of animals is not always sufficient, and the dosage is necessarily increased. It was the current situation that had to be. Therefore,
An object of the present invention is to provide a vitamin A preparation which is well soluble in water and exhibits excellent absorbability when orally administered to animals.
【０００４】[0004]
【課題を解決するための手段】本発明における上記の目
的は、ビタミンＡ、中鎖脂肪酸トリグリセリド、界面活
性剤、多価アルコールおよび水からなるビタミンＡ製剤
によって達成される。The above objects of the present invention are achieved by a vitamin A preparation comprising vitamin A, medium chain fatty acid triglyceride, surfactant, polyhydric alcohol and water.
【０００５】本発明において、ビタミンＡは、油状のも
のが好ましく、特にビタミンＡを１７０万ＩＵ以上含有
するものが好適に使用される。In the present invention, vitamin A is preferably oily, and particularly preferably vitamin A containing 1.7 million IU or more.
【０００６】中鎖脂肪酸トリグリセリドは、構成脂肪酸
が炭素数６乃至１０の飽和脂肪酸であるものが好まし
い。このような脂肪酸の例としては、カプロン酸、エナ
ント酸、カプリル酸、ペラゴン酸、カプリン酸等が挙げ
られ、特にカプリル酸、ペラゴン酸、カプリン酸が好適
である。The medium-chain fatty acid triglyceride is preferably one in which the constituent fatty acid is a saturated fatty acid having 6 to 10 carbon atoms. Examples of such fatty acids include caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid and the like, with caprylic acid, pelargonic acid and capric acid being particularly preferred.
【０００７】界面活性剤は、ビタミンＡの可溶化剤とし
て用いられ、例えば、ポリオキシエチレングリセリン脂
肪酸エステル、ポリオキシエチレンソルビタン脂肪酸エ
ステル、特に好ましくはポリオキシエチレン硬化ヒマシ
油、ポリオキシエチレンソルビタンモノオレートが使用
される。The surfactant is used as a solubilizing agent for vitamin A, for example, polyoxyethylene glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, particularly preferably polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan monooleate. Is used.
【０００８】多価アルコールは、可溶化時の粘性の低
下、可溶化状態の安定化に用いられ、好適に使用される
多価アルコールの例としては、グリセリンおよびプロピ
レングリコールが使用される。Polyhydric alcohols are used to reduce the viscosity during solubilization and stabilize the solubilized state, and glycerin and propylene glycol are preferably used as examples of polyhydric alcohols.
【０００９】ビタミンＡ、中鎖脂肪酸トリグリセリド、
界面活性剤および多価アルコールの混合割合は、臨界的
ではないが、ビタミンＡ１重量部に対して中鎖脂肪酸ト
リグリセリド０．１乃至３０重量部、好ましくは０．５
乃至５重量部を用いる。界面活性剤はビタミンＡと中鎖
脂肪酸トリグリセリドの重量和に対して１乃至１０倍、
より好ましくは１．２乃至６倍を用いる。多価アルコー
ルは界面活性剤１重量部に対して０．１乃至２重量部、
好ましくは０．５乃至１．５重量部用いるのが適当であ
る。水は適量使用される。Vitamin A, medium-chain fatty acid triglyceride,
The mixing ratio of the surfactant and the polyhydric alcohol is not critical, but 0.1 to 30 parts by weight of medium-chain fatty acid triglyceride, preferably 0.5 to 1 part by weight of vitamin A.
To 5 parts by weight are used. Surfactant is 1 to 10 times the weight sum of vitamin A and medium chain fatty acid triglyceride,
More preferably, 1.2 to 6 times is used. The polyhydric alcohol is 0.1 to 2 parts by weight with respect to 1 part by weight of the surfactant,
It is suitable to use 0.5 to 1.5 parts by weight. Water is used in an appropriate amount.
【００１０】[0010]
【作用】本発明の製剤は常法に従って製造される。例え
ば、油状のビタミンＡ１重量部を８０乃至９０℃に加温
したミキサーの釜の中に入れる。ミキサーの羽根を１０
０乃至３００ｒｐｍで攪拌しながら、中鎖脂肪酸トリグ
リセリドを０．５乃至５重量部添加し２乃至３分攪拌す
る。その後攪拌を続けながらビタミンＡと中鎖脂肪酸ト
リグリセリドの重量和に対して１．２乃至６倍の界面活
性剤を徐々に添加する。その後界面活性剤１重量部に対
して０．５乃至１．５重量部の多価アルコールを添加
し、２乃至３分攪拌した後適量の水を加え、攪拌しなが
ら室温まで冷却する。かくして得られた本発明のビタミ
ンＡ製剤は、水によく溶け、中鎖脂肪酸トリグリセリド
を含まない製剤に比べて動物の体内におけるビタミンＡ
の吸収が優れたものとすることができる。The preparation of the present invention is manufactured by a conventional method. For example, 1 part by weight of oily vitamin A is placed in a kettle of a mixer heated to 80 to 90 ° C. 10 blades of mixer
While stirring at 0 to 300 rpm, 0.5 to 5 parts by weight of medium chain fatty acid triglyceride is added and stirred for 2 to 3 minutes. Then, while continuing stirring, 1.2 to 6 times the amount of surfactant is gradually added to the weight sum of vitamin A and medium chain fatty acid triglyceride. Thereafter, 0.5 to 1.5 parts by weight of polyhydric alcohol is added to 1 part by weight of the surfactant, and after stirring for 2 to 3 minutes, an appropriate amount of water is added, and the mixture is cooled to room temperature with stirring. The vitamin A preparation of the present invention thus obtained dissolves well in water and has a higher level of vitamin A in the animal body than the preparation containing no medium-chain fatty acid triglyceride.
Can be excellently absorbed.
【００１１】[0011]
【実施例】次に実施例を示して本発明をさらに具体的に
説明する。８０℃に加温したミキサーの釜の中に１ｇ中
ビタミンＡとして１７５万ＩＵを含有するビタミンＡ油
８５．７ｇと、ビタミンＥとして９６％以上を含むビタ
ミンＥ油７８１．３ｇを投入した。ミキサーの羽根を２
００ｒｐｍで攪拌しながら中鎖脂肪酸トリグリセリドと
して、商品名「ヘルシップＦＯ−１００」（花王株式会
社製）を７５０ｇを投入し２分間攪拌した。その後グリ
セリン２・２５ｋｇを投入し２分間攪拌したのち、適量
の水を加えて全量を１０ｋｇとし室温まで冷却した。EXAMPLES Next, the present invention will be described more specifically by showing examples. 85.7 g of vitamin A oil containing 1.75 million IU of vitamin A in 1 g and 781.3 g of vitamin E oil containing 96% or more of vitamin E were placed in a kettle of a mixer heated to 80 ° C. 2 mixer blades
While stirring at 00 rpm, 750 g of trade name "Hellship FO-100" (manufactured by Kao Corporation) was added as a medium chain fatty acid triglyceride, and the mixture was stirred for 2 minutes. Then, 2.25 kg of glycerin was added and stirred for 2 minutes, and then an appropriate amount of water was added to bring the total amount to 10 kg and the mixture was cooled to room temperature.
【００１２】本製剤を試験区製剤とした。また、対照区
製剤としてビタミンＡとビタミンＥを同一量含み、中鎖
脂肪酸トリグリセリドを含まない製剤を同様の方法で調
整した。両製剤の吸収性を調査するために各製剤２００
ｇを体重約６０ｋｇの子牛（試験区４頭、対照区３頭）
に１回経口投与し、子牛の血清中におけるビタミンＡお
よびビタミンＥの経時的濃度を測定した。結果を図１お
よび図２に示した。図１および図２において○は中鎖脂
肪酸トリグリセリドを含有する試験区製剤、×は中鎖脂
肪酸トリグリセリドを含有しない対照区製剤を投与する
ことによる血清中のビタミンＡおよびビタミンＥの経時
的濃度を示す。This formulation was used as a test plot formulation. Further, as a control preparation, a preparation containing the same amount of vitamin A and vitamin E and not containing medium chain fatty acid triglyceride was prepared by the same method. To investigate the absorbability of both formulations, each formulation 200
Calf weighing about 60 kg (4 test plots, 3 control plots)
Was orally administered once to each of the animals and the time-dependent concentrations of vitamin A and vitamin E in calf serum were measured. The results are shown in FIG. 1 and FIG. In FIG. 1 and FIG. 2, ◯ indicates the concentration of vitamin A and vitamin E in serum over time by administering the test group preparation containing medium-chain fatty acid triglyceride and × the control preparation containing no medium-chain fatty acid triglyceride. .
【００１３】[0013]
【発明の効果】図１および図２より、本発明の製剤はビ
タミンＡおよびビタミンＥのどちらにおいても吸収性が
高いことが明らかである。図における吸収曲線下面積
（ＡＵＣ）より、ビタミンＡについては２７．７％、ビ
タミンＥについては１３．９％吸収性が改善された。以
上の結果より、ビタミンＡ製剤に中鎖脂肪酸トリグリセ
リドを配合することにより、ビタミンＡの動物の体内に
おける吸収性が高まることが明らかとなった。From the results shown in FIGS. 1 and 2, it is clear that the preparation of the present invention has high absorbability for both vitamin A and vitamin E. From the area under the absorption curve (AUC) in the figure, the absorbency was improved by 27.7% for vitamin A and 13.9% for vitamin E. From the above results, it has been clarified that the absorbability of vitamin A in the body of an animal is increased by adding a medium chain fatty acid triglyceride to the vitamin A preparation.
【図１】血清中のビタミンＡ濃度の経時変化を示すグラ
フである。FIG. 1 is a graph showing changes in serum vitamin A concentration over time.
【図２】血清中のビタミンＥ濃度の経時変化を示すグラ
フである。FIG. 2 is a graph showing changes with time of serum vitamin E concentrations.
図１および図２において○は試験区製剤、×は対照区製
剤の結果を示す。In FIG. 1 and FIG. 2, ∘ indicates the results of the test plot formulation and × indicates the results of the control plot.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 ＦＩ 技術表示箇所 Ａ６１Ｋ 31/355 Ａ６１Ｋ 31/355 47/10 47/10 Ｇ 47/14 47/14 Ｅ ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI Technical display location A61K 31/355 A61K 31/355 47/10 47/10 G 47/14 47/14 E
Claims (1)
ド、界面活性剤、多価アルコールおよび水からなる動物
用ビタミンＡ製剤。1. An animal vitamin A preparation comprising vitamin A, a medium-chain fatty acid triglyceride, a surfactant, a polyhydric alcohol and water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3258750A JP2538816B2 (en) | 1991-09-11 | 1991-09-11 | Vitamin A preparation for animals |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3258750A JP2538816B2 (en) | 1991-09-11 | 1991-09-11 | Vitamin A preparation for animals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0570371A JPH0570371A (en) | 1993-03-23 |
| JP2538816B2 true JP2538816B2 (en) | 1996-10-02 |
Family
ID=17324570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3258750A Expired - Fee Related JP2538816B2 (en) | 1991-09-11 | 1991-09-11 | Vitamin A preparation for animals |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2538816B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09194364A (en) * | 1996-01-22 | 1997-07-29 | Snow Brand Milk Prod Co Ltd | Vitamin a absorbefacient |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5747446A (en) * | 1980-09-05 | 1982-03-18 | Nippon Oil & Fats Co Ltd | Nutrious food composition |
| JPS59210867A (en) * | 1983-05-13 | 1984-11-29 | Taiyo Kagaku Kk | Nutrient food composition |
| JPS60153758A (en) * | 1984-01-23 | 1985-08-13 | Kao Corp | Fat or oil composition |
-
1991
- 1991-09-11 JP JP3258750A patent/JP2538816B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5747446A (en) * | 1980-09-05 | 1982-03-18 | Nippon Oil & Fats Co Ltd | Nutrious food composition |
| JPS59210867A (en) * | 1983-05-13 | 1984-11-29 | Taiyo Kagaku Kk | Nutrient food composition |
| JPS60153758A (en) * | 1984-01-23 | 1985-08-13 | Kao Corp | Fat or oil composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0570371A (en) | 1993-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4434159A (en) | Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom | |
| AU778889B2 (en) | Novel topical oestroprogestational compositions with systemic effect | |
| RU2246296C2 (en) | Composition comprising testosterone undecanoate and castor oil | |
| JP4209467B2 (en) | Formulation composition for oral administration | |
| WO2007067593A2 (en) | Self-emulsifyng formulations of cetp inhibitors | |
| JP2002541111A5 (en) | ||
| JPS6321648B2 (en) | ||
| JP6484393B2 (en) | Pharmaceutical composition containing dutasteride and capsule preparation containing the same | |
| US6271219B2 (en) | Topical formulations comprising skin penetration agents and the use thereof | |
| JP2557557B2 (en) | Pharmaceutical composition for topical administration containing piroxicam | |
| JP2538816B2 (en) | Vitamin A preparation for animals | |
| EP0582834A1 (en) | Pharmaceutical compositions containing esters of omega-3 polyunsatured acids and their use in the topical treatment of morbid affections | |
| JP4066466B2 (en) | Ointment containing sugar alcohols | |
| KR100426346B1 (en) | Pharmaceutical compositions for Hypercholesterolemia treatment using of Self Emulsifying drug delivery system | |
| JPH0681739B2 (en) | Aqueous liquid containing fat-soluble vitamin K | |
| EP0603405A1 (en) | Composition for treating acne vulgaris | |
| JPS62223119A (en) | Cream composition for external use | |
| JPS63230634A (en) | Transdermal preparation | |
| JP4162735B2 (en) | Rectal administration formulation containing serotonin receptor antagonist | |
| JPH10330250A (en) | Menatetrenone oily formulation | |
| JP2973077B2 (en) | Vitamin E preparation composition | |
| JP2017178798A (en) | External composition | |
| JP3202861B2 (en) | External preparation containing sulfonium compound | |
| JPS6333324A (en) | Composition for filling soft capsules | |
| JPS62164624A (en) | Gel preparation for external use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 19960409 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110708 Year of fee payment: 15 |
|
| LAPS | Cancellation because of no payment of annual fees |